President Trump announced a deal with Eli Lilly and Novo Nordisk on Thursday to lower the cost of their weight loss drugs for some Americans. Dr. Holly Lofton, NYU Langone Medical's weight management program director, joins "The Daily Report" to discuss.
Breakdown
- President Trump announced a deal with Eli Lilly and Novo Nordisk to lower the cost of weight-loss drugs for some Americans.
- Without insurance, GLP-1 injectable medications can cost over $1,300 per month, but the new plan lowers Wigovi's lowest dose to $245 and Zep-Bound's to $149 per month. 8s
- Lower prices could help 35 to 60 million Medicare and Medicaid beneficiaries access these drugs, which aid weight management and improve conditions like heart disease. 1m 1s
- Clinical trials show that diet and exercise alone result in minimal weight loss, while GLP-1 drugs offer greater health benefits and may reduce overall health care costs. 1m 31s
- Past restrictions on coverage stemmed from safety concerns in the 1990s, but current GLP-1 drugs are now recognized as safe and effective for long-term use. 2m 19s